Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients

Clinical Transplantation

Volumn 23, Issue 3, 2009, Pages 329-336

  Pons, Jose A ^a   Ramírez, Pablo ^a   Revilla Nuin, Beatriz ^a   Pascual, Domingo ^a   Baroja Mazo, Alberto ^a   Robles, Ricardo ^a   Sanchez Bueno, Francisco ^a   Martinez, Laura ^a   Parrilla, Pascual ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Cardiovascular risk; Liver transplantation; Renal dysfunction; Tolerance

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAFT RECIPIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY INFILTRATE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MEAN ARTERIAL PRESSURE; METABOLIC PARAMETERS; PATIENT COMPLIANCE; PORTAL VEIN; PRIORITY JOURNAL; RISK FACTOR; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; CREATININE; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; SURVIVORS;

EID: 66849124637     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00944.x     Document Type: Article

References (26)

1. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: A disease-specific analysis of the UNOS database. Liver Transpl 2004: 10: 886.
2. Furukawa H, Todo S. Evolution of immunosuppression in liver transplantation: Contribution of cyclosporine. Transplant Proc 2004: 36: 274S.
3. Scott LJ, Mc Keage K, Keam SJ, Plosker GL. Tacrolimus: A further update of its use in the management of organ transplantation. Drugs 2003: 63: 1247.
4. Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: The basis of graft acceptance. Hepatology 1993: 17: 1127. 1993
5. Mc Caughan GW. Withdrawal of immunosuppression in liver transplant recipients: Is this as good as it gets? Liver Transpl 2002: 8: 408.
6. Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997: 63: 243.
7. Devlin J, Doherty D, Thomson L et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998: 27: 926.
8. Pons JA, Yelamos J, Ramirez P et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation 2003: 75: 1045.
9. Takatsuki M, Uemoto S, Inomata Y et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001: 72: 449.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002: 39: S1.
11. Riordan SM, Williams R. Tolerance after liver transplantation: Does it exist and can immunosuppression be withdrawn? J Hepatol 1999: 31: 1106.
12. Bishop GA, Mc Caughan GW. Immune activation is required for the induction of liver allograft tolerance: Implications for immunosuppressive therapy. Liver Transpl 2001: 7: 161.
13. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001: 72: 1934.
14. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998: 66: 59.
15. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
16. Cohen AJ, Stegall MD, R osen CB et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002: 8: 916.
17. Neuberger J. Renal failure late after liver transplantation. Liver Transpl 2002: 8: 922.
18. Herrero JI, Quiroga J, Sangro B et al. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999: 5: 414.
19. Schlitt HJ, Barkmann A, Baker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001: 357: 587.
20. Moreno JM, Cuervas-Mons V, Rubio E et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2005: 5: 1120.
21. Sandborn WJ, Hay JE, Porayko MK et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994: 19: 925.
22. Falkenhain ME, Cosio FG, Sedmak DD. Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996: 62: 364.
23. Dische FE, Neuberger J, Keating J, Parsons V, Calne RY, Williams R. Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A. Lab Invest 1988: 58: 395.
24. Jain A, Reyes J, Kashyap R et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000: 232: 490.
25. Reuben A. Long-term management of the liver transplant patient: diabetes, hyperlipidemia, and obesity. Liver Transpl 2001: 7: S13.
26. Hollander AA, Van Saase JL, Kootte AM et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995: 345: 610.